<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961090</url>
  </required_header>
  <id_info>
    <org_study_id>104974</org_study_id>
    <nct_id>NCT00961090</nct_id>
  </id_info>
  <brief_title>Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery</brief_title>
  <official_title>A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthew R Quigley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DUSA Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A one time oral dose of ALA is taken before surgery. The medication makes the tumor visible
      under ultraviolet light which allow the surgeon to see more of the tumor for a more complete
      removal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with primary neoplastic brain tumors (Grades II-IV) will participate in this trial.
      Each patient will have been evaluated and found to have such a tumor by history and recent
      imaging studies (MRI) and deemed a surgical candidate based on current neurosurgical
      standards of care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 23, 2015</completion_date>
  <primary_completion_date type="Actual">April 22, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>More complete resection of malignant brain tumors</measure>
    <time_frame>3-7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of drug</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Single-Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single-Arm All subjects received 20mg/kg of Aminolevulinic Acid diluted in 50cc of water, orally, approximately 3 hours prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminolevulinic Acid</intervention_name>
    <description>20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery</description>
    <arm_group_label>Single-Arm</arm_group_label>
    <other_name>ALA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected primary brain tumor

          -  18 years of age or more

          -  Normal marrow and organ function

          -  Eastern Cooperative Group performance status â‰¤ 2

          -  Women of childbearing potential must use adequate birth control

          -  Ability to understand and willingness to sign a written informed consent form

          -  Life expectancy not a consideration

        Exclusion Criteria:

          -  Receiving any other investigational agents

          -  History of allergic reactions to ALA

          -  Personal or family history of porphyrias

          -  Liver disease in the past year

          -  Uncontrolled intercurrent illness

          -  Pregnant or lactating women

          -  Inability to undergo MRI with contrast
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew R Quigley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Guthrie Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <disposition_first_submitted>April 8, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>April 8, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 12, 2019</disposition_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)</investigator_affiliation>
    <investigator_full_name>Matthew R Quigley</investigator_full_name>
    <investigator_title>administrator</investigator_title>
  </responsible_party>
  <keyword>Brain tumor</keyword>
  <keyword>glioma</keyword>
  <keyword>surgical resection</keyword>
  <keyword>ALA</keyword>
  <keyword>ultraviolet light</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

